Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 27;8(1):35.
doi: 10.1186/s41181-023-00218-y.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Jean DaSilva  1 , Clemens Decristoforo  2 , Robert H Mach  3 , Guy Bormans  4 , Giuseppe Carlucci  5 , Mohammed Al-Qahtani  6 , Adriano Duatti  7 , Antony D Gee  8 , Wiktor Szymanski  9 , Sietske Rubow  10 , Jeroen Hendrikx  11 , Xing Yang  12 , Hongmei Jia  13 , Junbo Zhang  13 , Peter Caravan  14 , Hua Yang  15 , Jan Rijn Zeevaart  16 , Miguel Avila Rodriquez  17 , Ralph Santos Oliveira  18 , Marcela Zubillaga  19 , Tamer Sakr  20 , Sarah Spreckelmeyer  21
Affiliations
Review

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Jean DaSilva et al. EJNMMI Radiopharm Chem. .

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Main body: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

Conclusion: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Keywords: Highlight articles; Nuclear medicine; Radiochemistry; Radiopharmaceutical sciences; Radiopharmacy; Trends in radiopharmaceutical sciences.

PubMed Disclaimer

Conflict of interest statement

JDS, CD, RM, GB, GC, MAQ, AD, AG, WS, SR, JH, XY, HJ, JZ, PC, HY, JRZ, MAR, RSO, MZ and TS are in the Editorial Board. SS is part of the Associate Editors team.

Figures

Fig. 1
Fig. 1
Chemoenzymatic, one step synthesis of [18F]FDM and [18F]FSK from [18F]FDG, and their selective uptake in an in vivo model of MRSA myositis (red arrow: site of inoculation with live bacteria; white arrow: site of inoculation with heat-killed bacteria). With permission from J Am Chem Soc 2023;145:17632–17642 (CC BY 4.0 License)
Fig. 2
Fig. 2
A Schematic description of 68Ga-radiolabeling procedure along with timeline for synthesis of injection-ready 68Ga-31 using SPRP procedure and 68Ga-PSMA-617 using standard in solution protocol followed by secondary purification. B Radiochemical purity of crude labelling solution comparing solid phase vs. in-solution radiolabeling. C Non-decay corrected, end-of radiosynthesis yields for solid phase vs. in-solution radiolabeling. Yields reported as an average of n = 3 reactions
Fig. 3
Fig. 3
Illustration of solid-phase radiomatallation and photo triggered release. Adapted from Śmiłowicz et al.
Fig. 4
Fig. 4
Graphical abstract image and proof-of-concept of MMAAC. (Adapted with permission from Śmiłowicz et al. Copyright 2023 American Chemical Society.)
Fig. 5
Fig. 5
Chemical structure of the Tau tracer [18F]FPND-4
Fig. 6
Fig. 6
Interaction of F0502B with α-synuclein. With permission Creative Commons users license 561837064078
See this image and copyright information in PMC

References

    1. Ah-Thiane L, Ferrer L, Rousseau C. PSMA Is not specific to prostate cancer. J Nucl Med. 2023;64:1326. doi: 10.2967/jnumed.123.265720. - DOI - PubMed
    1. Baum RP, Singh A, Kulkarni HR, Bernhardt P, Ryden T, Schuchardt C, Gracheva N, Grundler PV, Koster U, Mueller D, Prohl M, Zeevaart JR, Schibli R, van der Meulen NP, Mueller C. First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC. J Nucl Med. 2021;62:1391–1397. doi: 10.2967/jnumed.120.258376. - DOI - PMC - PubMed
    1. Becker KV, Aluicio-Sarduy E, Bradshaw T, Hurley SA, Olson AP, Barrett KE, Batterton J, Ellison PA, Barnhart TE, Pirasteh A, Engle JW. Cyclotron production of 43Sc and 44gSc from enriched 42CaO, 43CaO and 44CaO targets. Front Chem. 2023;11:1167783. doi: 10.3389/fchem.2023.1167783. - DOI - PMC - PubMed
    1. Bernhardt P, Svensson J, Hemmingsson J, van der Meulen NP, Zeevaart JR, Konijnenberg MW, Mueller C, Kindblom J. Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer. Cancers. 2021;13:2011. doi: 10.3390/cancers13092011. - DOI - PMC - PubMed
    1. Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Koster U, Schibli R, van der Meulen NP, Mueller C. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113–1126. doi: 10.1007/s00259-021-05564-0. - DOI - PMC - PubMed